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INTRODUCTION
Breast cancer is one of most common malignancies in
women. It has been suggested that changes in many genes
encoding growth factors, growth factor receptors and other
regulators of proliferation might play a role in the tumori-
genesis and the response to breast cancer treatment (1). Re-
cently, an amazing improvement, which focused on the devel-
opment of molecular-targeting drugs, was achieved in anti-
cancer therapy. Clinical trials are currently testing monoclonal
antibodies and tyrosine kinase inhibitors against Her-2 and
EGFR, and other molecular strategies against their down-
stream targets including cyclin D1 (2, 3). Therefore, it is
important to evaluate the overall Her-2, EGFR, and cyclin
D1 status in targeting the gene product.
Molecular targeted therapy has been suggested in the treat-
ment of metastatic breast cancer. Trastuzumab is a high-affin-
ity, humanized, anti-Her-2 antibody for the treatment of
advanced breast carcinoma, particularly metastasis. Howev-
er, it was shown that less than half of patients with a high
level of Her-2 expression respond to Trastuzumab treatment
(4, 5). One explanation might be heterogeneity in the expres-
sion of Her-2 between primary and metastatic tumor cells
(6). It is also unclear whether protein overexpression or gene
amplification is more predictive in the response to the novel
modalities, such as small molecular inhibitors (7). Further-
more, there is no agreement as to whether the molecular sta-
tus should be assessed in primary tumors or metastases.
A change in the biological parameters is believed to occur in
the early stages of the progression of breast cancer and might
be maintained throughout cancer progression (8, 9). It is very
important to determine if the biological parameters in metas-
tatic regional lymph nodes are similar to that in the prima-
ry breast cancer because therapy is indicated for patients with
synchronous metastatic regional lymph nodes of breast can-
cer. In breast cancer, the axillary lymph nodes are often the
first sites to harbor metastases, and metastasis in this region
is the most powerful prognostic factor for breast cancer patients
(10). However, in most studies, the status of the targeted
molecules is determined on the primary tumor, and there are
a few reports regarding the comparison of Her-2 status be-
tween the primary and the metastatic lymph nodes (11-17).
Moreover, there have been no comprehensive studies evaluat-
ing gene amplification and protein expression in Her-2, EGFR,
and cyclin D1 in the metastatic lesions. To the best of our
knowledge, this is the first study to compare Her-2, EGFR,
and cyclin D1 status of primary breast tumors with their
metastatic lymph nodes using immunohistochemistry (IHC)
The significant advance in the development of molecular-targeting drugs has made
an evaluation of Her-2, EGFR, and cyclin D1 an important clinical issue in breast
cancer patients. This study compared the Her-2, EGFR, and cyclin D1 status of
primary tumors as well as their matching lymph node metastases using immuno-
histochemistry (IHC) and chromogenic in situ hybridization (CISH) in 73 breast
cancer patients. Her-2, EGFR, and cyclin D1 protein showed a concordance be-
tween the primary lesion and the metastatic regional lymph nodes in 82%, 90%,
and 63%, respectively. CISH also revealed 92%, 93%, and 85% concordance in
the gene amplification status of Her-2, EGFR, and cyclin D1, showing a reason-
able agreement between primary tumors and metastatic regional lymph nodes.
Although a statistically significant agreement was found in Her-2 expression, a rel-
atively high discordance rate (18%) raises a little concern. Our findings suggest
that the Her-2 status can be reliably assessed on primary tumor but a possible dif-
ference can be found in Her-2, EGFR, and cyclin D1 status between the primary
and the metastatic sites and this possibility should be concerned in patients con-
sidering molecular targeted therapy or patients with progress of disease.
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In this study, we compared the protein expression and gene
amplification of Her-2, EGFR, and cyclin D1 between pri-
mary breast cancer and the corresponding metastatic lymph
node using IHC and chromogenic CISH techniques, and
examined their association with the recurrence-free survival. 
MATERIALS AND METHODS
Sample collection 
Seventy-three cases of breast tumor from the surgical pathol-
ogy files of the Department of Pathology at Samsung Medi-
cal Center were investigated. The inclusion criteria were a
histopathological diagnosis of invasive breast carcinoma with
paired metastatic tumors in the lymph nodes, the availabili-
ty of clinical data, and the availability of paraffin-embedded
tissue specimens. All the patients had undergone surgery,
and had received neither chemotherapy nor radiotherapy
before the surgical resection. Table 1 shows the main char-
acteristics of the primary tumors. Breast cancer specimens
were reviewed using morphologic criteria according to the
WHO classification of breast cancer. All the patients were
women and the mean age was 47.77 yr (range, 28-70). The
mean number of metastatic lymph nodes was 4.95 (range
1-27, median 3.00). Raw survival data were obtained from
patients’ chart. The mean follow-up time was 45.5 (range,
1-63) months. Recurrence-free survival was expressed as the
number of months from diagnosis to the occurrence of an
event (local recurrence/metastasis).
Assembly of the tissue microarrays
The surgical specimens were fixed in 10% buffered for-
malin, processed, and embedded in paraffin using the stan-
dard protocol. The representative areas on the hematoxylin
and eosin (H&E)-stained sections were carefully selected and
marked on individual paraffin blocks. Two tissue cores (1-
mm diameter) were obtained from each primary carcinoma
sample and lymph node specimen, respectively. The tissue
cores were arrayed in a recipient paraffin block according to
the manufacturer’s instructions. 
Chromogenic in situ hybridization
The sections (4 μ m) were cut from the array blocks, trans-
ferred to adhesive-coated slides and air-dried in an incubator
for 16 hr at 65℃. The slides were deparaffinized in xylene
and graded ethanol followed by washing in phosphate-bu-
ffered saline (PBS). Microwave antigen retrieval was per-
formed in 100-mM Tris/50 mM EDTA, pH 7.0 at 93℃ for
15 min. After washing three times in PBS for 2 min each,
the slides were incubated in Digest-All 3 (Zymed, San Fran-
cisco, CA, U.S.A.) for 3 min at 37℃. After digestion, the
slides were washed in PBS, fixed in 10% phosphate-buffered
formalin for 1 min, and dehydrated through a 70%, 85%,
95%, and 100% ethanol series at room temperature. The
digoxigenin-labeled Her-2/neu (Zymed), EGFR (Zymed),
and cyclin D1 probes (Zymed) were placed on each slide,
and a coverslip was applied and sealed with rubber cement.
The slides were denatured for 3 min at 93℃ and incubated
at 37℃overnight in a humidified chamber. A posthybridiza-
tion wash was performed the next day, and immunodetec-
tion was performed at room temperature with a CISH poly-
mer detection Kit (Zymed) and 3,3′ -diaminobenzidine (DAB)
as the chromogen. The slides were counterstained with hema-
toxylin and mounted.
The CISH results were evaluated by optical microscopy at
low- and high- magnification, and scored as previously des-
cribed (18). High-level gene amplification was defined as
more than 10 discrete copies per nucleus or as large gene
copy clusters (observed as confluent masses containing more
than 10 signals) in more than 50% of the nuclei evaluated.
Low-level amplification was defined as 6 to 10 copies per
nucleus in more than 50% of cells. Unaltered gene copy was
defined as 1 to 5 copies per nucleus.
Immunohistochemistry
After deparaffinization and rehydration, 4-μ m thick sec-
tions on silane-coated slides were heat-pretreated in a citrate
buffer (pH 7.3 at 92℃ in microwave oven) and examined
by immunostaining using specific antibodies against Her-2
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Characteristics No. of patients (%)
Table 1. Clinicopathologic findings of the 73 primary breast
tumors
Age
<40 17 (23.3)
40-49 25 (34.2)
>50 31 (42.5)
Tumor size
<2 cm 18 (24.7)
2-4 cm 37 (50.7)
≥4 cm 18 (24.7)
No. of positive nodes
1-3 43 (58.9)
4-7 19 (26.0)
>7 11 (15.1)
Nuclear grade
1 2 (2.7)
2 37 (50.7)
3 34 (46.6)
Histologic grade
I 6 (8.2)
II 40 (54.8)
III 27 (37.0)(CB11; Novocastra Laboratories, Newcastle, U.K.), EGFR
(Novocastra Laboratories), and cyclin D1 (P2D11F11; Novo-
castra Laboratories). The avidin-biotin technique was applied
using DAB for visualization and hematoxylin for nuclear
counterstaining. 
Her-2 and EGFR immunoreactivity was assessed using
the following scoring approach: 0, no immunoreactivity or
immunoreactivity in <10% of tumor cells; 1+, faint weak
and incomplete staining of >10% of tumor cells; 2+, weak
to moderate complete membrane immunoreactivity in >10%
of tumor cells; 3+, moderate to strong complete membrane
immunoreactivity in >10% of tumor cells. The cyclin D1
protein is located in the cellular nucleus of the cells. The
Allred score was used to evaluate the cyclin D1 immunos-
tain (19). The proportion and intensity scores of cyclin D1
staining were added, and the staining was assessed as either:
0, no immunoreactivity; 1+, total scores 1-2; 2+, total scores
3-5; 3+, total scores 6-8. Cases interpreted as 0 or 1+ were
considered negative, and cases interpreted as 2+ or 3+ were
considered positive.
Statistical analysis
The agreement of Her-2, EGFR, or cyclin D1 status be-
tween primary tumors and matched metastatic lymph nodes
is expressed both by concordance and by the Cohen κcoeffi-
cient. The relation between the kappa value and the level of
agreement was suggested by Landis and Koch (20), with κ
values of 0.00-0.20 indicating slight agreement, 0.21-0.40
indicating fair agreement, 0.41-0.60 indicating moderate
agreement, 0.61-0.80 indicating substantial agreement, and
0.81-1.00 indicating almost perfect agreement. The Kaplan-
Meier method was used to estimate recurrence-free survival.
A log-rank test was applied to examine the relationship between
IHC or CISH data and recurrence-free survival. p values less
than 0.05 were considered to be statistically significant. Cal-
culations were done with SPSS 11.0 (SPSS, Inc., Chicago,
IL, U.S.A.). 
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Fig. 1. Comparison of immunostaining patterns of Her-2, EGFR and cyclin D1 in primary tumor and the corresponding metastatic lymph
node (LN) (×200). 3+/3+ expression of Her-2 in primary tumor (A) and LN (B); 2+/- expression of Her-2 in primary tumor (C) and LN (D);
1+/2+ expression of Her-2 in primary tumor (E) and LN (F), 3+/- expression of EGFR in primary tumor (G) and LN (H); -/2+ expression of
EGFR in primary tumor (I) and LN (J); -/3+ expression of cyclin D1 in primary tumor (K) and LN (L).
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Table 1 shows the clinical and pathologic characteristics
of 73 patients. Table 2, 3, and 4 show the comparisons of
Her-2, EGFR, and cyclin D1 status between the primary
lesions and matching metastatic regional lymph nodes,
respectively. Comparative features of IHC and CISH in the
primary lesions and paired metastatic regional lymph nodes
are depicted in Fig. 1 and 2.
Her-2 status in primary and paired metastatic carcinoma
in lymph node (Table 2)
Using IHC, 37.0% of the primary tumors and 32.8% of
the corresponding metastatic lymph node specimens over-
expressed Her-2. Among 73 cases, 60 (82.2%) cases showed
concordant expression between the primary tumors and
metastatic lymph nodes. Nine cases of 13 discordant cases
showed one-level difference of staining score. Regarding
CISH, 41.6% of the primary tumor specimens and 36.1%
of the corresponding metastatic lymph node specimens were
amplified. Only 6 (8.3%) of 73 cases showed discordant
results when the primary tumors and their metastatic lymph
nodes were compared. Four discordant cases were low-ampli-
fied lesions. IHC and CISH for HER2 status showed mod-
erate or perfect agreement with a κcoefficient of 0.609 (p<
0.001) and 0.824 (p<0.001), respectively. 
EGFR status in primary and paired metastatic carcinoma
in lymph node (Table 3)
Seventy cases were evaluated for EGFR IHC. EGFR-posi-
tivity was observed in 4 primary tumors (5.7%) and 5 meta-
static lymph nodes (7.1%). CISH analysis of the primary
and metastatic samples in 71 cases demonstrated 7.0% and
5.6% EGFR amplification, respectively. The EGFR status
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Fig. 2. Comparison of gene amplification patterns of Her-2, EGFR and cyclin D1 in primary tumor and the corresponding metastatic lymph
node (LN) (×400). High-level amplification/high-level amplification of Her-2 in primary tumor (A) and LN (B); high-level amplification/no
amplification of Her-2 in primary tumor (C) and LN (D); high-level amplification/no amplification of EGFR in primary tumor (E) and LN (F);
low-level amplification/low-level amplification of EGFR in primary tumor (G) and LN (H); high-level amplification/no amplification of cyclin
D1 in primary tumor (I) and LN (J); high-level amplification/high-level amplification of cyclin D1 in primary tumor (K) and LN (L).
A B C D
E F G H
I J K Lexamined with IHC and CISH showed 90.0% (63 out of 70
cases) and 92.9% (66 out of 71 cases) concordance between
the primary breast lesions and metastatic lymph nodes, respec-
tively. Changes in EGFR expression were from 2+ or 3+ to
0. The κcoefficient rates were 0.169 (p=0.153) and 0.407
(p=0.001) in IHC and CISH, respectively, showing moder-
ate agreement by CISH analysis. 
Cyclin D1 status in primary and paired metastatic carci-
noma in lymph node (Table 4)
For 73 cases examined by IHC, the cyclin D1 protein was
expressed in 52.1% of primary lesions and in 67.1% of me-
tastatic lymph nodes. Concordant cyclin D1 IHC results were
found in 43 cases (63.0%). Nineteen (70.4%) out of 27 dis-
cordant cases showed greater expression in the metastatic
sites. Seventy-one paired samples were simultaneously eval-
uated for CISH. There were 12 (16.9%) and 7 cases (9.8%)
with cyclin D1 amplification in both primary tumors and
metastatic lymph nodes, respectively. CISH analysis of the
primary and metastatic samples demonstrated 84.5% (60
out of 71 cases) concordance. In statistical analysis, the κcoef-
ficient was 0.250 (p=0.025) and 0.339 (p=0.003) in IHC
and CISH, respectively. CISH analysis showed fair agreement
between the primary and paired metastatic tumors.
Recurrence-free survival according to Her-2, EGFR, and
cyclin D1 status in primary mass and lymph node
Among 64 cases with follow-up, 12 patients had experi-
enced an event (local recurrence/metastasis) and one patient
with recurrence died of disease. Protein expression and gene
amplification of Her-2, EGFR, and cyclin D1 in primary
tumor and metastatic lymph node was not associated with
disease-free survival. However, there was a significant decrease
in disease-free survival in patients with EGFR amplification
in primary tumor and no EGFR amplification in metastatic
tumor (p=0.0454, Fig. 3). 
Regardless of Her-2 status in metastatic sites, three recur-
rent cases with Her-2 overexpression in primary tumors had
received Trastuzumab treatment and have been alive with-
out progress of disease. On the other hand, one patient who
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Variable
Immunohistochemistry 
(primary/metastatic tumor) (n=73)
+/+ +/-- /+ -/-
CISH
(primary/metastatic tumor) (n=73)
+/+ +/-- /+ -/-
No. of patients 19 (26.0%) 8 (11.0%) 5 (6.8%) 41 (56.2%) 25 (34.7%) 5 (6.9%) 1 (1.4%) 41 (56.9%)
Concordance 82.2% 91.7%
κ coefficient 0.609 (p<0.001) 0.825 (p<0.001)
No. of patients with recurrence 3 (25%) 1 (8.3%) 1 (8.3%) 7 (58.3%) 4 (33.3%) 0 0 8 (66.7%)
Table 2. Her-2 status in the primary and paired metastatic carcinoma in the lymph node
Variable
Immunohistochemistry 
(primary/metastatic tumor) (n=70)
+/+ +/-- /+ -/-
CISH
(primary/metastatic tumor) (n=71)
+/+ +/-- /+ -/-
No. of patients 1 (1.4%) 3 (4.3%) 4 (5.7%) 62 (88.6%) 2 (2.8%) 3 (4.2%) 2 (2.8%) 64 (90.1%)
Concordance 90.0% 93.0%
κ coefficient 0.169 (p=0.153) 0.407 (p=0.001)
No. of patients with recurrence 1 (9.1%) 0 1 (9.1%) 9 (81.8%) 0 2 (16.7%) 0 10 (83.3%)
Table 3. EGFR status in the primary and paired metastatic carcinoma in the lymph node
Variable
Immunohistochemistry
(primary/metastatic tumor) (n=73)
+/+ +/-- /+ -/-
CISH
(primary/metastatic tumor) (n=71)
+/+ +/-- /+ -/-
No. of patients 30 (41.1%) 8 (11.0%) 19 (26.0%) 16 (21.9%) 4 (5.6%) 8 (11.3%) 3 (4.2%) 56 (78.9)
Concordance 63% 84.5%
κ coefficient 0.250 (p=0.025) 0.339 (p=0.003)
No. of patients with recurrence 3 (25%) 2 (16.7%) 5 (41.7%) 2 (16.7%) 1 (8.3%) 1 (8.3%) 1 (8.3%) 9 (75%)
Table 4. Cyclin D1 status in the primary and paired metastatic carcinoma in the lymph node
CISH, chromogenic in situ hybridization.
CISH, chromogenic in situ hybridization. 
CISH, chromogenic in situ hybridization. had Her-2 protein overexpression in metastatic lymph node
but no immunoreactivity in primary tumor, has been suffer-
ing from progressive metastasis (Table 2).
DISCUSSION
The important role of targeted therapy against molecules
contributing to tumor development, progression, and metas-
tasis has attracted considerable attention. Molecular-target-
ing drugs against Her-2, EGFR, and cyclin D1 are a major
concern in breast cancer patients (2, 3). These molecules are
mainly evaluated at the primary site and there is little data
available regarding the markers between the primary tumor
and the corresponding metastases. However, the death of
metastatic cells is the main goal of treatment in a metastatic
setting. These cells may be biologically different from the
primary tumor, which has implications for the clinical man-
agement of breast cancer. Therefore, it is essential to deter-
mine if there is homogeneous biological marker expression
between primary tumor and its metastatic sites. In breast
carcinoma, a lymph node metastasis is an indicator of a poor
prognosis and represents the beginning of the progression
from local to systemic disease, which poses serious challenges
with regard to treatment. Although lymph node metastases
should not be assumed to be biologically equivalent to dis-
tant metastases, it has been hypothesized that there are sub-
tle genetic difference between the primary tumor and lymph
node metastases (21).
Her-2 is the most promising biological marker in terms
of predictive value for breast cancer treatment. Although
not complete, a number of studies have reported a high level
of consistency in the Her-2 status between primary tumors
and locoregional metastases using IHC and fluorescence in
situ hybridization (FISH) (11-17). Most data have shown a
good overall concordance of Her-2 status between primary
and metastatic tumors (11, 13, 14, 17). However, some data
have shown disagreement in up to 20% of tumors (22). The
present study demonstrated relatively good accordance of the
Her-2 status between the primary lesion and the metastatic
regional lymph node (82% and 92% when analyzed by IHC
or CISH, respectively). In particular, Her-2 amplification
showed strong agreement compared with the moderate agree-
ment of Her-2 overexpression. These findings suggest that
metastatic breast carcinoma in lymph nodes generally over-
expresses Her-2 in a manner similar to the corresponding
primary tumors, and Her-2 gene is stable in a metastasis.
However, the discordance rate of Her-2 overexpression in the
present study was relatively high (18%), and this fact could
not be completely ignored. In addition, fascinating findings
were observed in the follow-up results of the stratified sub-
groups according to the Her-2 status in primary and metastat-
ic tumors. Without reference to Her-2 status in metastatic
sites, three recurrent cases with Her-2 overexpression in pri-
mary tumors and Trastuzumab treatment for metastatic di-
asease have been alive with no progress of disease by this time.
On the other hand, one patient who had Her-2 protein over-
expression in the metastatic lymph node but no immunore-
activity in primary lesion, has been suffering from progressive
metastatic disease during follow-up and she did not receive
treatment with Trastuzumab as her tumor was negative for
Her-2. Although present study included small number of
informative cases, our results suggests that Her-2 evaluation
in metastatic sites can benefit from treatment with Trastuzum-
ab when Her-2 is negative in the primary tumor.
There have been few studies that have evaluated EGFR or
cyclin D1 status in metastatic tumors (23-25). Tsutsui et al.
demonstrated a strong concordance rate (92%) of EGFR
immunoreactivity between the primary breast cancers and
matching regional lymph nodes (25). However, the most
recent study demonstrated that EGFR expression is not sta-
ble during metastatic progression in a significant propor-
tion of primary lung cancer (26). The present study demon-
strated insignificant correlation of EGFR protein expression
(p=0.153) between the primary lesions and the metastatic
regional lymph node in spite of the high concordance ob-
served (90.0%). On the other hand, the EGFR gene in the
primary and corresponding metastatic lesions revealed mod-
erate agreement even though showed similar concordance
to EGFR protein expression. This statistical finding might
be induced by low positive rate of EGFR expression and fur-
ther studies with larger numbers of patients are needed to
verify our results. In the present study, the positive rate of
EGFR staining seems to be lower than that of previous reports,
but is consistent with the result of Bhargava et al. using the
same scoring system (27).
Regarding cyclin D1, Hao et al. demonstrated that 61 out
of 86 paired samples exhibited no difference in cyclin D1
expression (23). In 9 out of 86 cases, the cyclin D1 expres-
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Fig. 3. Recurrence-free survival according to EGFR amplification.
Disease-free survival is significantly low in patients with EGFR
amplification in primary tumor and no EGFR amplification in me-
tastatic tumor (p=0.0454).sion level was higher in the metastasis samples, whereas the
expression level was lower in the metastases of 16 out of 86
cases. They reported a trend toward decreasing cyclin D1
expression in metastases despite the lack of statistical signif-
icance. In this study, discordant results were observed in 27
out of 73 cases by IHC and 11 out of 71 cases by CISH. The
frequency of cyclin D1 overexpression was higher in the metas-
tases but the level of amplification showed fair agreement
between primary and corresponding metastatic lymph nodes.
In this study, the cyclin D1 protein was overexpressed more
frequently than amplification, again within the range of fre-
quencies previously described for breast cancer patients (28,
29). Although the immunohistochemical reactivity of cyclin
D1 has been evaluated by various methods, cyclin D1 over-
expression is observed in up to 68% of primary breast can-
cers, and the frequency of cyclin D1 protein overexpression
exceeded the frequency of DNA amplification (30-32). The
significance of cyclin D1 protein or gene as prognostic fac-
tors for survival in breast cancer patients is still controver-
sial (33). Although cyclin D1 overexpression has been report-
ed to indicate resistance to tamoxifen treatment, cyclin D1
amplification was reported to be a more powerful predictor
of a successful tamoxifen treatment particularly in node-pos-
itive patients (34). Therefore, the overall evaluation of the
cyclin D1 status using IHC and FISH would be helpful in
selection of patients who may benefit from targeted therapy. 
IHC and FISH are the preferred methods for evaluating
protein overexpression and gene amplification because of
their ability to distinguish the tumor’s morphological fea-
tures. The critical advantages of IHC over FISH are the lower
cost and easy automation. Therefore, IHC can be performed
in most pathology laboratories without the requirement of a
fluorescence microscope. Compared with IHC, FISH pro-
vides an accurate assessment of the gene copy number and is
the universally accepted gold standard for evaluating gene
amplification. However, this technique is not ideally suited
for tissue microarrays because it is difficult and time consum-
ing to navigate through the tissue microarray section under
a fluorescent microscope. CISH was recently introduced to
visualize gene alteration with an IHC-like peroxidase reac-
tion and has been reported to be a good substitution for FISH.
This method only requires an ordinary microscope rather
than an expensive fluorescence microscope. The CISH sig-
nals are more familiar to the pathologists and morphologi-
cal detail is more easily appreciated in bright field and there-
fore quicker to observe in tissue microarray slides. In this
study, CISH was performed successfully on tissue microar-
ray sections without any technical problem. Our study demon-
strates that CISH is a useful tool to easily assess Her-2, EGFR,
and cyclin D1 genes in surgical laboratory.
In this study, tissue microarray (TMA) techniques allowed
the rapid and high throughput of IHC and CISH. TMA has
been used for IHC and FISH techniques, and is a highly reli-
able method through avoiding day-to-day variability in the
staining conditions as well as in the interpretation of the
staining results. However, the study using TMA may have
the limitations of the representative of the selected samples
because of tumor heterogeneity. This can be avoided by punch-
ing two or more cores from different areas (35). We made
TMA blocks with two tissue cores (1-mm diameter) from
each primary carcinoma sample and lymph node specimen,
respectively. We think that two cores of 1-mm diameter spec-
imen are representative to perform IHC or CISH to some
degree, although we cannot completely exclude the limita-
tion of the study using TMA.
Most previous reports have shown a good concordance rate
of Her-2 status between primary and metastatic tumors.
Compared the previous reports based on the status of sam-
plings such as whole paraffin blocks or TMA samples, the
concordance rate of Her-2 status between the primary and
the metastatic sites is not different (80-100% in whole paraf-
fin specimen [11-14, 17, 22, 25] vs. 93% in TMA speci-
men [16]). Because a study that revealed a relatively high
discordance rate of 20% was performed using whole paraf-
fin specimen (22), lack of concordance in the study seems to
result from clonal selection or genetic drifts in metastatic
sites rather than tumor heterogeneity.
In conclusion, our results suggest that Her-2 status tends
to be stable during metastatic progression in a significant
proportion of breast cancer but a possible difference in Her-
2, EGFR, and cyclin D1 status between the primary and the
metastatic sites would be concerned for breast cancer patients
considering molecular targeting therapy. Since it is not yet
unclear which is more predictable in the response of molec-
ular targeting therapy, protein overexpression or gene ampli-
fication, CISH along with IHC may be implemented in rou-
tine assessment of Her-2, EGFR and cyclin D1 status for
breast cancer patients.
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